Frinze Laboratories Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 04-01-2025
- Paid Up Capital ₹ 2.00 Cr
as on 04-01-2025
- Company Age 18 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 5.10 Cr
as on 04-01-2025
- Revenue -73.87%
(FY 2022)
- Profit -68.94%
(FY 2022)
- Ebitda -63.56%
(FY 2022)
- Net Worth 54.67%
(FY 2022)
- Total Assets 15.79%
(FY 2022)
About Frinze Laboratories
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 2.00 Cr.
The company currently has active open charges totaling ₹5.10 Cr.
Raveendra Velagapudi, Velagapudi Prameela, Uppala Rao, and One other member serve as directors at the Company.
- CIN/LLPIN
U24231TG2006PTC051094
- Company No.
051094
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
08 Sep 2006
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Frinze Laboratories?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Uppala Rao  | Managing Director | 08-Sep-2006 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Raveendra Velagapudi | Director | 01-Dec-2007 | Current |
| Velagapudi Prameela | Director | 08-Sep-2006 | Current |
Seetaram Srungaram  | Director | 24-Jan-2008 | Current |
Financial Performance of Frinze Laboratories.
Frinze Laboratories Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 73.87% decrease. The company also saw a substantial fall in profitability, with a 68.94% decrease in profit. The company's net worth Soared by an impressive increase of 54.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Frinze Laboratories?
In 2022, Frinze Laboratories had a promoter holding of 40.13% and a public holding of 59.88%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 19 Aug 2023 | ₹1.78 M | Open |
Hdfc Bank Limited Creation Date: 16 Jun 2023 | ₹3.00 M | Open |
Hdfc Bank Limited Creation Date: 31 Dec 2009 | ₹4.63 Cr | Open |
How Many Employees Work at Frinze Laboratories?
Frinze Laboratories has a workforce of 24 employees as of Mar 21, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Frinze Laboratories, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Frinze Laboratories's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
